Navigation Links
Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
Date:8/24/2010

and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

Advanced Life Science recently announced that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of Restanza to treat CABP.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Laboratories, Inc. (NASDAQ: IDXX ) today reported ... 11% versus the prior year period to $390 million. ... of 2014 versus the prior year period was 9%, ... . Earnings per diluted share ("EPS") for the quarter ... year period to $1.10."In the second quarter, we continued ...
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3
... March 19, 2012 Novartis Pharmaceuticals Corporation today ... 75 mcg is now available in the US ... is indicated for the long-term maintenance bronchodilator treatment ... obstructive pulmonary disease (COPD), including chronic bronchitis and/or ...
... Incorporated (Nasdaq: ARAY ), the premier radiation ... 2012 Industry Excellence Award by Microsoft® as part of the ... be honored at Convergence 2012 , the premier Microsoft ... Texas. The 2012 Customer Excellence Awards, which are ...
Cached Medicine Technology:Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 3Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 4Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 5Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 6Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 7Accuray Receives Microsoft Dynamics® Customer Excellence Award 2Accuray Receives Microsoft Dynamics® Customer Excellence Award 3Accuray Receives Microsoft Dynamics® Customer Excellence Award 4
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... of Dangerous Synthetic Marijuana Increasing (7/3), the state of ... synthetic marijuana, more so even than cocaine. Officials believe the ... safe because it's a “form” of marijuana. However, both doctors ... truth. Going so far as to call it “poison,” doctors ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... As reported by Wood TV 8 in ... Michigan has seen a nearly 500-person increase in heroin related ... was 271 between 1999 and 2002, the toll increased to ... like other states, drug users in Michigan have turned to ... He compared the price of both substances, noting that an ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... executives who have almost 50 years of hospital negotiating experience. Our ... a focus of expertise to help buyers become even more effective. ... all hospital purchases. There is finally help. , ... ...
... rituximab causes considerable kidney injury healing in patients with ... to a study appearing in the November 2008 issue ... Nephrology (CJASN) . The results suggest that this condition, ... percent of cases, can actually be healed in some ...
... Ill., Aug. 5 Healthation CEO Scott Kornhauser,announced ... Services. Collins brings to Healthation more than 20 ... include Vice President of Professional Services of,Aptiv Technology ... will be focused on leading, recruiting, and managing ...
... of Princeton psychology researchers has developed a computer program ... what it is about certain human faces that makes ... they have also found that the program allows them ... or dominant faces possible. , Such work could have ...
... carts from Eagle MHC are designed for maximum cleanability and sterile ... ... -- http://www.eaglegrp.com/ [Steril-Eze® surgical case carts] from Eagle MHC ... product line - which encompasses a wide range of choices in ...
... (NPF) announced it will fund $3.7 million in ... outreach worldwide.,Grants were awarded to institutions in the ... care centers, and 10 outreach,centers. Through centers alone, ... and almost 70,000 patients with movement disorders., ...
Cached Medicine News:Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease 2Health News:Whom do we fear or trust? 2Health News:Whom do we fear or trust? 3Health News:New Steril-Eze Surgical Case Carts from Eagle MHC Feature Rugged, Easy-Clean Design 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2
ARION is a long-pulsed alexandrite laser system with a wavelength of 755 nm...
... to connect an infusion ... pump, and then to ... order to conduct urodynamics ... Laborie Medical Technologies infusion ...
Used for suprapubic monitoring of bladder pressures. Suprapubic urodynamic studies avoid the effects of urethral catheterization and eliminate the need for a double bladder puncture. Supplied sterile...
... Triage® Cardiac Panel is a ... rapid quantitative determination of CK-MB, ... ethylenediaminetetraacetic acid (EDTA) whole blood ... is used as an aid ...
Medicine Products: